IP Library Granted Patent US 8,354,422
Granted Patent B2
US 8,354,422 · App. 12/788,008 · Granted Jan 15, 2013

Pyrimidine inhibitors of kinase activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,354,422
App. No.
12/788,008
Granted
Jan 15, 2013
Kind
B2
Abstract

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , R 2 , R 3 , R 4 , R 5 , n, p, q, Ar 1 , and Ar 2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.

Claims (129)

1. A compound of formula (I)

or a pharmaceutically acceptable salt, or a combination thereof, wherein

G 1 is formula (i), (ii), (iii), or (iv)

m is 0, 1, 2, 3, or 4;

m′ is 0, 1, 2, or 3;

m″ is 0, 1, or 2;

n is 0, 1, or 2;

p is 0, 1, 2, 3, or 4;

R 1 , R 2 , and R 3 are optional substituents, and if present, are each independently alkyl, halogen, —O(alkyl), —O(haloalkyl), or haloalkyl;

a and b designate the points of attachment at which formula (i), (ii), (iii), (iv) are bound to formula (I);

R 4 and R 5 , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl;

q is 1, 2, 3, or 4;

Ar 1 is aryl or heteroaryl; each of which is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents as represented by T, wherein each T is selected from the group consisting of oxo, alkyl, alkenyl, alkynyl, halogen, haloalkyl, CN, NO 2 , G 2 , —OR 6 , —OC(O)R 7 , —SR 6 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 N(R 8 )(R 9 ), —N(R 8 )(R 9 ), —N(R 8 )C(O)R 7 , —N(R 8 )C(O)OR 7 , —N(R 8 )S(O) 2 R 7 , —N(R 8 )C(O)N(R 8 )(R 9 ), —N(R 8 )C(O)—(C 1-6 alkylenyl)-N(R 8 )(R 9 ), —N(R 8 )S(O) 2 N(R 8 )(R 9 ), —C(O)R 6 , —C(O)OR 6 , —C(O)N(R 8 )(R 9 ), —(C 1-6 alkylenyl)-G 2 , —(C 1-6 alkylenyl)-OR 6 , —(C 1-6 alkylenyl)-OC(O)R 7 , —(C 1-6 alkylenyl)-SR 6 , —(C 1-6 alkylenyl)-S(O)R 7 , —(C 1-6 alkylenyl)-S(O) 2 R 7 , —(C 1-6 alkylenyl)-S(O) 2 N(R 8 )(R 9 ), —(C 1-6 alkylenyl)-N(R 8 )(R 9 ), —(C 1-6 alkylenyl)-N(R 8 )C(O)R 7 , —(C 1-6 alkylenyl)-N(R 8 )C(O)OR 7 , —(C 1-6 alkylenyl)-N(R 8 )S(O) 2 R 7 , —(C 1-6 alkylenyl)-N(R 8 )C(O)N(R 8 )(R 9 ), —(C 1-6 alkylenyl)-N(R 8 )S(O) 2 N(R 8 )(R 9 ), —(C 1-6 alkylenyl)-C(O)R 6 , —(C 1-6 alkylenyl)-C(O)OR 6 , and —(C 1-6 alkylenyl)-C(O)N(R 8 )(R 9 ),

two substituents on the vicinal carbon atoms of Ar 1 , together with the carbon atoms to which they are attached, optionally form a monocyclic 5- or 6-membered heterocycle containing one or two heteroatoms selected from N(H), O, S, S(O), or S(O) 2 , wherein each of the monocyclic ring is optionally substituted with 1, 2, 3, or 4 alkyl groups;

each occurrence of R 6 and R 9 are each independently hydrogen, alkyl, haloalkyl, —(C 1-6 alkylenyl)-CN, —(C 1-6 alkylenyl)-OH, —(C 1-6 alkylenyl)-C(O)OH, G 3 , or —(C 1-6 alkylenyl)-G 3 ;

each occurrence of R 7 is independently alkyl, haloalkyl, —(C 1-6 alkylenyl)-CN, —(C 1-6 alkylenyl)-OH, G 3 , or —(C 1-6 alkylenyl)-G 3 ;

each occurrence of R 8 is independently hydrogen, alkyl, or haloalkyl;

each occurrence of G 2 is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, each of which is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of G 3 , —(C 1-6 alkylenyl)-G 3 , and R 10 ,

each occurrence of G 3 is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, each of which is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 R 10 groups;

Ar 2 is aryl or heteroaryl, each of which is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 R 10 groups;

each occurrence of R 10 is independently alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, CN, NO 2 , —OR Z1 , —OC(O)R Z2 , —SR Z1 , —S(O)R Z2 , —S(O) 2 R Z2 , —S(O) 2 N(R Z3 )(R Z4 ), —N(R Z3 )(R Z4 ), —N(R Z3 )C(O)R Z2 , —N(R Z3 )C(O)OR Z2 , —N(R Z3 )S(O) 2 R Z2 , —N(R Z3 )C(O)N(R Z3 )(R Z4 ), —N(R Z3 )S(O) 2 N(R Z3 )(R Z4 ), —C(O)R Z1 , —C(O)OR Z1 , —C(O)N(R Z3 )(R Z4 ), —(C 1-6 alkylenyl)-OR Z1 , —(C 1-6 alkylenyl)-OC(O)R Z2 , —(C 1-6 alkylenyl)-SR Z1 , —(C 1-6 alkylenyl)-S(O)R Z2 , —(C 1-6 alkylenyl)-S(O) 2 R Z2 , —(C 1-6 alkylenyl)-S(O) 2 N(R Z3 )(R Z4 ), —(C 1-6 alkylenyl)-N(R Z3 )(R Z4 ), —(C 1-6 alkylenyl)-N(R Z3 )C(O)R Z2 , —(C 1-6 alkylenyl)-N(R Z3 )C(O)OR Z2 , —(C 1-6 alkylenyl)-N(R Z3 )S(O) 2 R Z2 , —(C 1-6 alkylenyl)-N(R Z3 )C(O)N(R Z3 )(R Z4 ), —(C 1-6 alkylenyl)-N(R Z3 )S(O) 2 N(R Z3 )(R Z4 ), —(C 1-6 alkylenyl)-C(O)R Z1 , —(C 1-6 alkylenyl)-C(O)OR Z1 , or —(C 1-6 alkylenyl)-C(O)N(R Z3 )(R Z4 ),

each occurrence of R Z1 , R Z3 , and R Z4 , are each independently hydrogen, alkyl, or haloalkyl; and

each occurrence of R Z2 is independently alkyl or haloalkyl.

2. The compound according to claim 1 having formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl.

3. The compound according to claim 1 having formula (I-i) or a pharmaceutically acceptable salt thereof

wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, p, q, Ar 1 , and Ar 2 are as set forth in claim 1 .

4. The compound according to claim 3 having formula (I-i), or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl.

5. The compound according to claim 3 having formula (I-i), or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 1 are optionally substituted phenyl.

6. The compound according to claim 3 having formula (I-i), or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl, and Ar 1 is optionally substituted heteroaryl.

7. The compound according to claim 1 having formula (I-ii) or a pharmaceutically acceptable salt thereof

wherein R 1 , R 2 , R 3 , R 4 , R 5 , m′, n, p, q, Ar 1 , and Ar 2 are as set forth in claim 1 .

8. The compound according to claim 7 having formula (I-ii), or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl.

9. The compound according to claim 7 having formula (I-ii), or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 1 are optionally substituted phenyl.

10. The compound according to claim 1 having formula (I-iii) or a pharmaceutically acceptable salt thereof

wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, p, q, Ar 1 , and Ar 2 are as set forth in claim 1 .

11. The compound according to claim 10 having formula (I-iii), or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl.

12. The compound according to claim 10 having formula (I-iii), or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 1 are optionally substituted phenyl.

13. The compound according to claim 1 having formula (I-iv) or a pharmaceutically acceptable salt thereof

wherein R 1 , R 2 , R 3 , R 4 , R 5 , m″, n, p, q, Ar 1 , and Ar 2 are as set forth in claim 1 .

14. The compound according to claim 13 having formula (I-iv), or a pharmaceutically acceptable salt thereof, wherein Ar 2 is optionally substituted phenyl.

15. The compound according to claim 13 having formula (I-iv), or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 1 are optionally substituted phenyl.

16. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxyphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-[3-(methylsulfonyl)phenyl]pyrimidin-2-amine;

3-[(4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-N,N-dimethylbenzenesulfonamide;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-phenylpyrimidin-2-amine;

4-{2-[4-(benzyloxy)-2-fluorophenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-fluorophenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-2-methylphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-chlorophenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-(2-{4-[(2-methoxybenzyl)oxy]phenyl}imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-(2-{4-[(4-methoxybenzyl)oxy]phenyl}imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-(2-{4-[(2-fluorobenzyl)oxy]phenyl}imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-(2-{4-[(3-fluorobenzyl)oxy]phenyl}imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-(2-{4-[(4-fluorobenzyl)oxy]phenyl}imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine;

N-{3-[2-(dimethylamino)ethyl]phenyl}-4-{2-[4-(1-phenylethoxy)phenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(4-chloro-2-methoxyphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[4-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[3-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(3-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine;

2-{4-[(4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-1H-pyrazol-1-yl}ethanol;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(4-fluorophenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2,4-difluorophenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[3-(2-pyrrolidin-1-ylethoxy)phenyl]pyrimidin-2-amine;

2-[{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}(ethyl)amino]ethanol;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[4-(1,1-dioxidothiomorpholin-4-yl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[2-methoxy-5-(methylsulfonyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-[2-methoxy-5-(methylsulfonyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;

2-[(2-{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}ethyl)(methyl)amino]ethanol;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[2-methoxy-5-(trifluoromethyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-[2-methoxy-5-(trifluoromethyl)phenyl]pyrimidin-2-amine;

N 1 -(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)-2-methoxy-N 4 ,N 4 -dimethylbenzene-1,4-diamine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl}pyrimidin-2-amine;

2-(4-{4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}piperazin-1-yl)ethanol;

1-({4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-3-methoxyphenyl}amino)-2-methylpropan-2-ol;

N 1 -(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)-2-methoxybenzene-1,4-diamine;

2-{4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-1H-pyrazol-1-yl}ethanol;

2-[{4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-3-methoxyphenyl}(methyl)amino]ethanol;

4-{2-[4-(benzyloxy)-3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-ethylphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-4-thiomorpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-5-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-{4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-3-methoxyphenyl}glycine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[1-(2-piperidin-1-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[2-methoxy-4-(4-thiomorpholin-4-ylpiperidin-1-yl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-4-piperidin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-3-yl}-N-[3-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{5-[2-(dimethylamino)ethyl]-2-methoxyphenyl}pyrimidin-2-amine;

N-(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-amine;

N-(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine;

N-(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[4-(1,1-dioxidothiomorpholin-4-yl)-2-methoxyphenyl]pyrimidin-2-amine;

2-[{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-4-methoxybenzyl}(methyl)amino]ethanol;

N 1 -{4-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}-N 2 ,N 2 -dimethylglycinamide;

N 1 -{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}-N 2 ,N 2 -dimethylglycinamide;

N 1 -{3-[(4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]phenyl}-N 2 ,N 2 -dimethylglycinamide;

4-{2-[4-(benzyloxy)-3-methylphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-{4-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

1-{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]benzyl}pyrrolidin-3-ol;

N 1 -{3-[(4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-4-methoxyphenyl}-N 2 ,N 2 -dimethylglycinamide;

N 1 -{3-[(4-{2-[4-(benzyloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-4-methoxyphenyl}-N 2 ,N 2 -dimethylglycinamide;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-(2-methoxy-5-thiomorpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[4-(benzyloxy)-3-methoxyphenyl]imidazo[1,2-a]pyridin-3-yl}-N-[5-(1,1-dioxidothiomorpholin-4-yl)-2-methoxyphenyl]pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{2-[4-(benzyloxy)phenyl]-6-fluoropyrazolo[1,5-a]pyridin-3-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine;

4-{6-[4-(benzyloxy)phenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-phenylpyrimidin-2-amine;

4-{6-[4-(benzyloxy)phenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-(2-methoxyphenyl)pyrimidin-2-amine;

4-{6-[4-(benzyloxy)phenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}pyrimidin-2-amine;

N 1 -(4-{6-[4-(benzyloxy)-3-methoxyphenyl]imidazo[2,1-b][1,3]thiazol-5-yl}pyrimidin-2-yl)-2-methoxy-N 4 ,N 4 -dimethylbenzene-1,4-diamine

4-{6-[4-(benzyloxy)-3-methoxyphenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-[2-(pyrrolidin-1-ylmethyl)phenyl]pyrimidin-2-amine;

4-{6-[4-(benzyloxy)-3-methoxyphenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-{4-[dimethylamino)methyl]phenyl}pyrimidin-2-amine;

4-{6-[4-(benzyloxy)-3-methoxyphenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}pyrimidin-2-amine; and

4-{6-[4-(benzyloxy)-3-methoxyphenyl]imidazo[2,1-b][1,3]thiazol-5-yl}-N-{3-[2-(dimethylamino)ethyl]phenyl}pyrimidin-2-amine.

17. A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carrier.

18. A method of treating cancer in a mammal comprising administering thereto a therapeutically effective amount of a compound of claim 1 or pharmaceutically acceptable salt thereof, wherein the cancer is bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer or thyroid cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030137/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2010
From: CLARK, RICHARD F.; BELL, RANDY L.; BA-MAUNG, NWE Y.; ERICKSON, SCOTT A.; FIDANZE, STEVE D.; MANTEI, ROBERT A.; SHEPPARD, GEORGE S.; SORENSEN, BRYAN K.; WANG, GARY T.; WANG, JIEYI
To: ABBOTT LABORATORIES
Reel/Frame 024824/0299 →